Transactions
8
Insider / HALOZYME THERAPEUTICS, INC.
Daly James M
Director at HALOZYME THERAPEUTICS, INC.
- Company
- HALOZYME THERAPEUTICS, INC.
- First filing on record
- January 20, 2026
- Latest trade on record
- October 16, 2026
- SEC filings
- EDGAR ↗
Daly James M, Director at HALOZYME THERAPEUTICS, INC., has disclosed 8 transactions in CYTK, HALO since January 20, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $50K at the reported prices. The latest was filed October 20, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
1.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Daly James M reported 8 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 8 | 10,830 | $50K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 8 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | Other A | October 16, 2026 | October 20, 2026 | 4d | 195 | $64 | $12K | Form 4 ↗ | ||
| HALO | Other A | October 1, 2026 | October 2, 2026 | 1d | 1,775 | — | — | derivative | Form 4 ↗ | |
| HALO | Other A | October 1, 2026 | October 2, 2026 | 1d | 1,169 | — | — | Form 4 ↗ | ||
| CYTK | Other A | July 15, 2026 | July 16, 2026 | 1d | 151 | $83 | $12K | Form 4 ↗ | ||
| CYTK | Other A | May 27, 2026 | May 27, 2026 | 0d | 4,301 | — | — | derivative | Form 4 ↗ | |
| CYTK | Other A | May 27, 2026 | May 27, 2026 | 0d | 2,851 | — | — | Form 4 ↗ | ||
| CYTK | Other A | April 15, 2026 | April 15, 2026 | 0d | 191 | $65 | $12K | Form 4 ↗ | ||
| CYTK | Other A | January 15, 2026 | January 20, 2026 | 5d | 197 | $63 | $12K | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 20, 2026 | Form 4 | 0001061983-26-000103 | 1 | published | EDGAR ↗ |
| October 2, 2026 | Form 4 | 0001159036-26-000136 | 2 | published | EDGAR ↗ |
| July 16, 2026 | Form 4 | 0001061983-26-000078 | 1 | published | EDGAR ↗ |
| May 27, 2026 | Form 4 | 0001061983-26-000061 | 2 | published | EDGAR ↗ |
| April 15, 2026 | Form 4 | 0001061983-26-000037 | 1 | published | EDGAR ↗ |
| January 20, 2026 | Form 4 | 0001061983-26-000010 | 1 | published | EDGAR ↗ |
Other insiders at HALOZYME THERAPEUTICS, INC.
- Torley Helen PRESIDENT AND CEO 182 rows
- Callos Andrew EVP, Chief Commercial Officer 71 rows
- Malik Fady Ibraham EVP Research & Development 70 rows
- Blum Robert I President & CEO 52 rows
- Lee Sung EVP, Chief Financial Officer 38 rows
- Snyder Mark Howard SVP, CHIEF LEGAL OFFICER 23 rows
- Caudill Cortney SVP, CHIEF OPERATING OFFICER 19 rows
- LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER 18 rows
- Kaye Edward M. MD Director 17 rows
- WIERENGA WENDELL Director 16 rows
Everyone on file, with contracts and lobbying under the company's name: HALOZYME THERAPEUTICS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 8 | January 20, 2026 | October 20, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.